×
Arcellx Net Profit Margin 2021-2024 | ACLX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Arcellx net profit margin from 2021 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Arcellx Net Profit Margin 2021-2024 | ACLX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Arcellx net profit margin from 2021 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$146.3B
Gilead Sciences (GILD)
$114.5B
Bristol Myers Squibb (BMY)
$114.2B
Vertex Pharmaceuticals (VRTX)
$108.7B
CSL (CSLLY)
$83.4B
Regeneron Pharmaceuticals (REGN)
$74.9B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$38.7B
Alnylam Pharmaceuticals (ALNY)
$31.8B
BioNTech SE (BNTX)
$26.8B
Illumina (ILMN)
$21.7B
BeiGene (ONC)
$20.5B
Biogen (BIIB)
$20.5B
Incyte (INCY)
$13.9B
Genmab (GMAB)
$13.8B
Genmab (GNMSF)
$13.7B
Intra-Cellular Therapies (ITCI)
$13.4B
Moderna (MRNA)
$13.1B
Insmed (INSM)
$13B
Bio-Techne Corp (TECH)
$12B
BioMarin Pharmaceutical (BMRN)
$11.7B
Sarepta Therapeutics (SRPT)
$11.3B
Vaxcyte (PCVX)
$10.6B
QIAGEN (QGEN)
$10.5B
Exelixis (EXEL)
$10.3B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Exact Sciences (EXAS)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.5B
Repligen (RGEN)
$9B
Roivant Sciences (ROIV)
$8.1B